Inoue Daisuke, Matsumoto Toshio
Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School, Institute of Health Biosciences.
Nihon Rinsho. 2006 Sep;64(9):1633-8.
Osteoporosis is a skeletal disease characterized by increased risk of fracture due to reduced bone strength. Osteoporosis-associated fractures not only impair patients' quality of life (QOL) but also diminishes life expectancy. The most important goal in the treatment of osteoporosis is fracture prevention. To achieve this goal, in addition to lifestyle changes including balanced diet, increased exercise and fall prevention, most high-risk patients need pharmacological intervention. Based on the currently available evidence, the first-line medications are bisphosphonates and raloxifene. Active vitamin D alone may not be efficacious enough but may particularly be important in Japan as a surrogate for vitamin D and calcium supplementation. A new bone anabolic therapy by parathyroid hormone (PTH), which is already in clinical use in other countries, is also expected to become available in Japan in the near future.
骨质疏松症是一种骨骼疾病,其特征是由于骨强度降低导致骨折风险增加。与骨质疏松症相关的骨折不仅会损害患者的生活质量(QOL),还会缩短预期寿命。骨质疏松症治疗的最重要目标是预防骨折。为实现这一目标,除了进行生活方式的改变,包括均衡饮食、增加运动和预防跌倒外,大多数高危患者还需要药物干预。根据目前可得的证据,一线药物是双膦酸盐和雷洛昔芬。单独使用活性维生素D可能不够有效,但在日本作为维生素D和钙补充剂的替代物可能特别重要。甲状旁腺激素(PTH)的一种新的骨合成代谢疗法已在其他国家临床应用,预计在不久的将来也将在日本上市。